Shockwave Therapy vs. Viagra for ED: What the Evidence Actually Shows in 2026

Viagra (sildenafil) remains the clear first-line choice for most men with erectile dysfunction — guideline-endorsed, fast-acting, and backed by decades of randomized trial data. Low-intensity shockwave therapy is a genuinely interesting alternative, but it carries experimental status, inconsistent protocols, and a $3,000+ price tag that the evidence doesn't yet fully justify for the average patient.

How Each Treatment Works

PDE5 inhibitors block the enzyme that breaks down cGMP, sustaining smooth muscle relaxation and blood inflow. The key caveat: the drug amplifies a signal that must already exist. Men with severe neurogenic ED or profound endothelial failure often see blunted responses [1].

Shockwave therapy takes a structurally different approach. Li-ESWT delivers acoustic pulses — typically around 0.09–0.10 mJ/mm² — inducing controlled microtrauma thought to stimulate angiogenesis via VEGF release and recruit endothelial progenitor cells [5][6]. The ambition is restorative: rebuild the vasculature so spontaneous erections return without ongoing medication. The clinical proof, however, is still catching up.

For men who want proven, on-demand symptom control, comparing licensed online ED providers is a practical starting point before investing in procedural options.

What the Clinical Evidence Actually Shows

The data for Viagra are solid. In a 26-week dose-escalation trial of 315 men, 79–82% reported improved erections on sildenafil versus 23–24% on placebo [2]. Long-term open-label data across 979 men followed four years showed satisfaction above 94% annually, with less than 3% per year discontinuing due to insufficient response [8]. AUA guidelines place oral PDE5 inhibitors as first-line therapy with the highest evidence grade.

The shockwave data are more complicated. A double-blind RCT in the Journal of Urology found 79% of Li-ESWT recipients met the IIEF-EF minimal clinically important difference at three months, versus 0% in the sham group [7]. But a Cochrane review of 21 RCTs concluded overall certainty of evidence remains low, citing heterogeneous protocols and inconsistent effect sizes [4]. Durability data suggest peak benefit around 12 months, with measurable decline by year two to three [3]. ISSM and SMSNA both currently categorize Li-ESWT as investigational — a classification that matters when generic sildenafil costs under $1/dose.

If Viagra-class drugs haven't worked, see what ED treatments are worth trying when Viagra fails for second-line options including BiMix/TriMix injectables and Eroxon topical, which received FDA approval in 2023.

Who Is Actually a Candidate?

Cleveland Clinic's guidance is practical: shockwave therapy is most appropriate for men with mild-to-moderate vasculogenic ED who already respond at least partially to PDE5 inhibitors [3]. Men with primarily neurogenic or psychogenic ED are generally poor candidates [3][6].

The realistic use case is a man who responds to Viagra but wants to reduce medication dependence. Pairing a urologist consultation with a telehealth evaluation through Strut Health — which offers PDE5 inhibitor prescriptions and referral guidance — can help clarify whether a procedural workup makes sense. The full sexual health treatment resource covers the clinical ladder from first-line through advanced options.

---

Related reading

• When Viagra Fails: The Best ED Treatments to Try Next in 2026
• Acoustic Wave Therapy for ED: Does It Actually Work in 2026?

Frequently asked questions

Is shockwave therapy better than Viagra for erectile dysfunction?

Viagra (sildenafil) remains the superior first-line choice for most men with erectile dysfunction based on current evidence, while shockwave therapy carries investigational status from both the ISSM and SMSNA. In a 26-week trial of 315 men, sildenafil produced improved erections in 79–82% of patients versus 23–24% on placebo, a level of evidence that Li-ESWT cannot yet match. The Cochrane systematic review of 21 randomized controlled trials rated the overall certainty of shockwave evidence as low, citing heterogeneous protocols and inconsistent effect sizes [4].

How long does shockwave therapy last compared to Viagra?

Shockwave therapy offers a potentially longer-lasting structural benefit, with peak results appearing around 12 months, but measurable decline has been observed by years two to three [3]. Viagra, by contrast, works on demand within a predictable timeframe but requires ongoing use, with long-term open-label data across 979 men showing sustained satisfaction rates above 94% annually over four years [8]. Generic sildenafil is available for under $1 per dose, making continuous use far more economical than shockwave therapy's $3,000–$3,500 out-of-pocket cost.

Who is a good candidate for shockwave therapy instead of Viagra?

Shockwave therapy is most appropriate for men with mild-to-moderate vasculogenic ED who already respond at least partially to PDE5 inhibitors like sildenafil or tadalafil [3]. Men with primarily neurogenic ED — such as post-prostatectomy or diabetic neuropathy cases — or psychogenic ED are generally considered poor candidates for Li-ESWT [6]. The realistic use case is a patient who responds to Viagra but wants to reduce medication dependence, though large sham-controlled trials with long follow-up have not yet rigorously confirmed durable PDE5 inhibitor elimination post-treatment.